JP2019512002A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019512002A5 JP2019512002A5 JP2018539317A JP2018539317A JP2019512002A5 JP 2019512002 A5 JP2019512002 A5 JP 2019512002A5 JP 2018539317 A JP2018539317 A JP 2018539317A JP 2018539317 A JP2018539317 A JP 2018539317A JP 2019512002 A5 JP2019512002 A5 JP 2019512002A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- antibody
- seq
- acid sequence
- nos
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021153453A JP2022023052A (ja) | 2016-02-04 | 2021-09-21 | ヒト化抗ｃｄ３抗体、その複合体、およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662291143P | 2016-02-04 | 2016-02-04 | |
| US62/291,143 | 2016-02-04 | ||
| PCT/US2017/016407 WO2017136659A2 (en) | 2016-02-04 | 2017-02-03 | Humanized anti-cd3 antibodies, conjugates and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021153453A Division JP2022023052A (ja) | 2016-02-04 | 2021-09-21 | ヒト化抗ｃｄ３抗体、その複合体、およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019512002A JP2019512002A (ja) | 2019-05-09 |
| JP2019512002A5 true JP2019512002A5 (cg-RX-API-DMAC7.html) | 2020-03-26 |
| JP6951826B2 JP6951826B2 (ja) | 2021-10-20 |
Family
ID=59501004
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018539317A Active JP6951826B2 (ja) | 2016-02-04 | 2017-02-03 | ヒト化抗ｃｄ３抗体、その複合体、およびその使用 |
| JP2021153453A Pending JP2022023052A (ja) | 2016-02-04 | 2021-09-21 | ヒト化抗ｃｄ３抗体、その複合体、およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021153453A Pending JP2022023052A (ja) | 2016-02-04 | 2021-09-21 | ヒト化抗ｃｄ３抗体、その複合体、およびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12252534B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3411069B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6951826B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102891788B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN109069635B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017213886B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3013463C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2992761T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017136659A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2968552T (pt) | 2013-03-14 | 2020-05-18 | Scripps Research Inst | Anticorpo dos agentes alvo, combinações e uso para os mesmos |
| ES2992761T3 (en) | 2016-02-04 | 2024-12-17 | Scripps Research Inst | Humanized anti-cd3 antibodies, conjugates and uses thereof |
| EP3668898B1 (en) | 2017-08-14 | 2023-07-05 | MorphoSys AG | Humanized antibodies for cd3 |
| KR101973060B1 (ko) * | 2017-10-20 | 2019-04-26 | 주식회사 녹십자 | 항-cd3 항체 및 이를 포함하는 암 치료용 약학적 조성물 |
| EP3844188A1 (en) | 2018-08-28 | 2021-07-07 | Ambrx, Inc. | Anti-cd3 antibody folate bioconjugates and their uses |
| WO2020135804A1 (zh) * | 2018-12-29 | 2020-07-02 | 上海一宸医药科技有限公司 | 异源二聚体融合蛋白 |
| CN116178547A (zh) * | 2019-02-22 | 2023-05-30 | 武汉友芝友生物制药股份有限公司 | Cd3抗原结合片段及其应用 |
| US20200392230A1 (en) * | 2019-05-14 | 2020-12-17 | Qlb Biotherapeutics | Bispecific anti-cd3 x cd20 antibodies and uses thereof |
| KR102878895B1 (ko) | 2019-05-21 | 2025-10-31 | 노파르티스 아게 | Cd19 결합 분자 및 이의 용도 |
| EP4039707A4 (en) * | 2019-09-30 | 2022-11-16 | Harbour Biomed (Shanghai) Co., Ltd | Cd3-targeting antibody, bispecific antibody and use thereof |
| WO2021098834A1 (zh) * | 2019-11-22 | 2021-05-27 | 上海一宸医药科技有限公司 | Psma抗体及其应用 |
| WO2021173889A1 (en) | 2020-02-26 | 2021-09-02 | Ambrx, Inc. | Uses of anti-cd3 antibody folate bioconjugates |
| TWI827807B (zh) * | 2020-02-26 | 2024-01-01 | 香港商潤俊（中國）有限公司 | 抗cd3抗體葉酸生物共軛物及其用途 |
| BR112023003366A2 (pt) | 2020-08-25 | 2023-05-09 | Gilead Sciences Inc | Moléculas multiespecíficas de ligação ao antígeno que têm como alvo hiv e métodos de uso |
| CN114853897B (zh) * | 2021-04-15 | 2024-01-26 | 北京大学深圳研究生院 | 抗cd19/cd22/cd3三特异性抗体及用途 |
| EP4384218A4 (en) * | 2021-08-09 | 2025-11-05 | Merck Patent Gmbh | Proteins that uncouple T-lymphocyte-mediated tumor cytotoxicity from the release of pro-inflammatory cytokines |
| IL314993A (en) | 2022-02-23 | 2024-10-01 | Xencor Inc | Anti-cd28 x anti-psma antibodies |
| CN120603604A (zh) * | 2022-11-18 | 2025-09-05 | Jn生物科学有限责任公司 | 抗cd3抗体 |
| CN120569191A (zh) | 2022-11-23 | 2025-08-29 | 乔治亚大学研究基金公司 | 用于增加免疫应答的组合物及其使用方法 |
| KR20240139569A (ko) * | 2023-03-13 | 2024-09-23 | 머스트바이오 주식회사 | 신규한 cd3 결합항체 및 이를 포함한 다중특이 항체 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| EP1291360A1 (en) | 1991-12-13 | 2003-03-12 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| EP1034298B1 (en) | 1997-12-05 | 2011-11-02 | The Scripps Research Institute | Humanization of murine antibody |
| US20020142000A1 (en) | 1999-01-15 | 2002-10-03 | Digan Mary Ellen | Anti-CD3 immunotoxins and therapeutic uses therefor |
| US6256533B1 (en) | 1999-06-09 | 2001-07-03 | The Procter & Gamble Company | Apparatus and method for using an intracutaneous microneedle array |
| AU2002341792B2 (en) | 2001-09-21 | 2007-09-06 | The Administrators Of The Tulane Educational Fund | Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof |
| US7122622B2 (en) | 2002-04-16 | 2006-10-17 | Biosynthema Inc. | Peptide compounds having improved binding affinity to somatostatin receptors |
| CA2523716C (en) | 2003-05-31 | 2014-11-25 | Micromet Ag | Human anti-human cd3 binding molecules |
| JP4937737B2 (ja) | 2004-03-30 | 2012-05-23 | 株式会社クレハ | 非水電解質二次電池用負極材料、その製造方法、負極および電池 |
| BRPI0508761A (pt) | 2004-03-31 | 2007-08-14 | Genentech Inc | anticorpo humanizado, composição que compreende um anticorpo humanizado, ácido nucléico isolado, vetor, célula hospedeira, processo de produção de anticorpo humanizado, método de tratamento de disfunção tgf-beta, método de detecção de tgf-beta, artigo industrializado e método de tratamento de cáncer |
| WO2007042261A2 (en) | 2005-10-11 | 2007-04-19 | Micromet Ag | Compositions comprising cross-species-specific antibodies and uses thereof |
| WO2007058725A2 (en) | 2005-10-12 | 2007-05-24 | The Regents Of The University Of California | Engineered antibody fragment that irreversibly binds an antigen |
| EP1951890A4 (en) | 2005-11-16 | 2009-06-24 | Ambrx Inc | PROCESSES AND COMPOSITIONS WITH NON-NATURAL AMINO ACIDS |
| CN101448512B (zh) | 2005-12-14 | 2015-11-25 | Ambrx公司 | 含有非天然氨基酸和多肽的组合物、涉及非天然氨基酸和多肽的方法以及非天然氨基酸和多肽的用途 |
| CN105085313A (zh) | 2005-12-30 | 2015-11-25 | Ambrx公司 | 含有非天然氨基酸和多肽的组合物、涉及非天然氨基酸和多肽的方法以及非天然氨基酸和多肽的用途 |
| JP2009523815A (ja) | 2006-01-19 | 2009-06-25 | アンブルックス，インコーポレイテッド | 免疫原性が調節された非天然アミノ酸ポリペプチド |
| WO2011028195A2 (en) | 2006-12-18 | 2011-03-10 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
| JP2010514808A (ja) | 2006-12-28 | 2010-05-06 | アンブルックス，インコーポレイテッド | フェナジンまたはキノキサリンで置換されたアミノ酸およびポリペプチド |
| US9193763B2 (en) | 2007-08-17 | 2015-11-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
| US8536310B2 (en) | 2007-10-17 | 2013-09-17 | Arca Biopharma, Inc. | Antibodies to CLL-1 |
| US9308257B2 (en) | 2007-11-28 | 2016-04-12 | Medimmune, Llc | Protein formulation |
| PL2291659T3 (pl) | 2008-05-13 | 2016-04-29 | Univ Yale | Małe cząsteczki chimerowe do rekrutacji przeciwciał do komórek nowotworowych |
| KR101732054B1 (ko) | 2008-09-26 | 2017-05-02 | 암브룩스, 인코포레이티드 | 비천연 아미노산 복제 의존성 미생물 및 백신 |
| WO2012098238A1 (en) | 2011-01-21 | 2012-07-26 | Novimmune S.A. | Combination therapies and methods using anti-cd3 modulating agents and anti-il-6 antagonists |
| WO2012142659A1 (en) | 2011-04-19 | 2012-10-26 | Baker Idi Heart And Diabetes Institute Holdings Limited | Site-selective modification of proteins |
| CN107722124A (zh) * | 2011-05-21 | 2018-02-23 | 宏观基因有限公司 | 能够与人和非人cd3结合的cd3结合分子 |
| EP3170821B1 (en) | 2011-05-27 | 2021-09-15 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives |
| DK2714684T3 (en) | 2011-05-27 | 2018-11-26 | Ambrx Inc | COMPOSITIONS CONTAINING, PROCEDURE INVOLVING, AND APPLICATIONS OF NON-NATURAL AMINO ACID-BONDED DOLASTATIN DERIVATIVES |
| US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| CA3111357A1 (en) | 2011-12-23 | 2013-06-27 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
| DK2900694T3 (en) | 2012-09-27 | 2018-11-19 | Merus Nv | BISPECIFIC IGG ANTIBODIES AS T-CELL ACTIVATORS |
| US10087250B2 (en) | 2012-10-08 | 2018-10-02 | Roche Glycart Ag | Fc-free antibodies comprising two fab-fragments and methods of use |
| US9273093B2 (en) | 2012-10-11 | 2016-03-01 | Protagonist Therapeutics, Inc. | α4β7 peptide dimer antagonists |
| US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
| US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
| EP2961770A1 (en) | 2013-02-26 | 2016-01-06 | Roche Glycart AG | Bispecific t cell activating antigen binding molecules |
| PT2968552T (pt) * | 2013-03-14 | 2020-05-18 | Scripps Research Inst | Anticorpo dos agentes alvo, combinações e uso para os mesmos |
| WO2014185985A1 (en) | 2013-05-14 | 2014-11-20 | Ambrx, Inc. | Novel polypeptide small molecule conjugates and their uses |
| AP2015008888A0 (en) | 2013-06-07 | 2015-11-30 | Rhizen Pharmaceuticals Sa | Dual selective pi3 delta and gamma kinase inhibitors |
| ES2741308T3 (es) | 2013-10-15 | 2020-02-10 | Scripps Research Inst | Interruptores de células T con receptores de antígenos quiméricos y usos de los mismos |
| EP3176185A1 (en) | 2013-11-04 | 2017-06-07 | Glenmark Pharmaceuticals S.A. | Production of t cell retargeting hetero-dimeric immunoglobulins |
| CN106029696B (zh) | 2013-12-17 | 2020-07-28 | 基因泰克公司 | 抗cd3抗体及使用方法 |
| RU2718692C2 (ru) | 2014-05-29 | 2020-04-13 | Мэкроудженикс, Инк. | Триспецифичные связывающие молекулы, которые специфически связывают антигены множества злокачественных опухолей, и способы их применения |
| AU2015292406B2 (en) | 2014-07-25 | 2021-03-11 | Cytomx Therapeutics, Inc | Anti-CD3 antibodies, activatable anti-CD3 antibodies, multispecific anti-CD3 antibodies, multispecific activatable anti-CD3 antibodies, and methods of using the same |
| EP3283113A4 (en) | 2015-04-15 | 2018-12-05 | The California Institute for Biomedical Research | Optimized pne-based chimeric receptor t cell switches and uses thereof |
| ES2992761T3 (en) | 2016-02-04 | 2024-12-17 | Scripps Research Inst | Humanized anti-cd3 antibodies, conjugates and uses thereof |
-
2017
- 2017-02-03 ES ES17748229T patent/ES2992761T3/es active Active
- 2017-02-03 CN CN201780024266.1A patent/CN109069635B/zh active Active
- 2017-02-03 US US16/074,600 patent/US12252534B2/en active Active
- 2017-02-03 EP EP17748229.6A patent/EP3411069B1/en active Active
- 2017-02-03 WO PCT/US2017/016407 patent/WO2017136659A2/en not_active Ceased
- 2017-02-03 JP JP2018539317A patent/JP6951826B2/ja active Active
- 2017-02-03 CA CA3013463A patent/CA3013463C/en active Active
- 2017-02-03 KR KR1020187025472A patent/KR102891788B1/ko active Active
- 2017-02-03 AU AU2017213886A patent/AU2017213886B2/en active Active
-
2021
- 2021-09-21 JP JP2021153453A patent/JP2022023052A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019512002A5 (cg-RX-API-DMAC7.html) | ||
| AR111361A1 (es) | Anticuerpos biespecíficos de unión específica a pd1 y lag3 | |
| CY1120414T1 (el) | Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους | |
| WO2015138907A3 (en) | Hybrid immunoglobulin containing non-peptidyl linkage | |
| FI3683235T3 (fi) | Anti-IL-33-vasta-aineita ja niiden käyttöjä | |
| CY1114851T1 (el) | Il-1βητα δεσμευτικα αντισωματα και θραυσματα αυτων | |
| JP2013530929A5 (cg-RX-API-DMAC7.html) | ||
| AR095980A1 (es) | Anticuerpos biespecíficos específicos para fap (proteína de activación fibroblástica) y dr5 (receptor de muerte 5), anticuerpos específicos para dr5 y métodos de utilización | |
| AR109355A2 (es) | Moléculas de unión al receptor ox40 humano | |
| RU2015147300A (ru) | Гуманизированные антитела к cxcr5, их производные и их применение | |
| CY1118008T1 (el) | Πρωτεϊνες δεσμευσης ετεροδιμερους και χρησεις αυτων | |
| AR077088A1 (es) | Proteinas biespecificas de union a antigeno | |
| JP2017518083A (ja) | ｉｎ ｖｉｖｏでの非共有結合的連結のための方法および組成物 | |
| JP2016538240A5 (cg-RX-API-DMAC7.html) | ||
| JP2005120106A5 (cg-RX-API-DMAC7.html) | ||
| AR075882A1 (es) | Anticuerpo antagonista especifico para el heterodimero de alfa-4-beta-7 | |
| CN102838663B (zh) | 定点突变和定点修饰的病毒膜蛋白、其制备方法及其应用 | |
| AR110755A1 (es) | Anticuerpos dirigidos a hueso | |
| RU2018104703A (ru) | Опухолеспецифичное антитело против egfr и его применение | |
| NZ598770A (en) | Monoclonal antibodies | |
| Okochi et al. | Array-based rational design of short peptide probe-derived from an anti-TNT monoclonal antibody | |
| JP2013538791A5 (cg-RX-API-DMAC7.html) | ||
| ECSP18084153A (es) | Anticuerpos anti-BASIGIN humanizados y uso de los mismos | |
| WO2019104155A3 (en) | Chemical probe-dependent evaluation of protein activity and uses thereof | |
| RU2015154792A (ru) | Выделенный антиген лейкоцидина Staphylococcus aureus, антитело, специфически связывающееся с субъединицей LukGH и способ определения связывания или токсичности двухкомпонентного цитолизина LukGH Staphylococcus aureus |